Collegium Pharmaceutical, Inc. COLL Symproic and other — Total amortization expense

Other product segments

Similar metrics at other companies

NABLSubscription and other revenue — Amortization of acquired technologies

$4.24M+0.2%

RBBNAmortization Of Acquired Technology — Cost Of Goods And Services Sold Amortization

$4.56M-15.3%

PRSUService — Cost Of Goods And Services Sold Amortization

$700K0.0%

TONXMarket Live — Cost Of Goods And Services Sold Amortization

$0-100%

AVAVMw — Cost Of Goods And Services Sold Amortization

$231.25K-27.1%

AVAVUxs — Cost Of Goods And Services Sold Amortization

$4.62M+50.5%

FAQ

What is Collegium Pharmaceutical, Inc.'s symproic and other — total amortization expense?

Collegium Pharmaceutical, Inc. (COLL) reported symproic and other — total amortization expense of $1.82M in Q4 2025.

How has Collegium Pharmaceutical, Inc.'s symproic and other — total amortization expense changed year-over-year?

Collegium Pharmaceutical, Inc.'s symproic and other — total amortization expense decreased by 0.0% year-over-year, from $1.82M to $1.82M.

What is the long-term trend for Collegium Pharmaceutical, Inc.'s symproic and other — total amortization expense?

Over 2 years (2023 to 2025), Collegium Pharmaceutical, Inc.'s symproic and other — total amortization expense has grown at a 0.0% compound annual growth rate (CAGR), from $7.29M to $7.29M.

What does symproic and other — total amortization expense mean?

The periodic non-cash expense allocated to the Symproic segment to reflect the systematic reduction in the value of finite-lived intangible assets. This metric is essential for understanding the impact of acquisition-related costs on the segment's reported operating profitability.